Biosimilars: presumption of guilt
Some chronic systemic diseases, including diabetes mellitus, require the life-long use of biotechnological medical products, of which quality,effectiveness and safety depends the duration and quality of life for patients.Patent protection expiry of many original biological agents has assumed the key...
Main Authors: | Marina Vladimirovna Shestakova, Olga Konstantinovna Vikulova |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2011-12-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://dia-endojournals.ru/dia/article/viewFile/5825/3584 |
Similar Items
-
Options to optimize the access to biosimilars: analysis and solutions
by: O. V. Kirsanova, et al.
Published: (2018-05-01) -
Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01) -
Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01) -
Revising the Guidance Document for Biosimilar Agents
by: Steven Williams
Published: (2017-04-01) -
Generics and biosimilars in oncology
by: I. A. Gopienko, et al.
Published: (2020-04-01)